Abstract: The present invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of elagolix or a pharmaceutically acceptable salt thereof. Further, the present invention specifically relates to a stable oral elagolix or pharmaceutically acceptable salt thereof in a tablet dosage form and the process of preparation thereof. Additionally, the present invention provides a stable elagolix or pharmaceutically acceptable salt thereof in a tablet dosage form for the effective treatment of endometriosis, uterine fibroids, polycystic ovary syndrome, or adenomyosis.
| # | Name | Date |
|---|---|---|
| 1 | 202417043024-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [03-06-2024(online)].pdf | 2024-06-03 |
| 2 | 202417043024-STATEMENT OF UNDERTAKING (FORM 3) [03-06-2024(online)].pdf | 2024-06-03 |
| 3 | 202417043024-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [03-06-2024(online)].pdf | 2024-06-03 |
| 4 | 202417043024-FORM 1 [03-06-2024(online)].pdf | 2024-06-03 |
| 5 | 202417043024-DECLARATION OF INVENTORSHIP (FORM 5) [03-06-2024(online)].pdf | 2024-06-03 |
| 6 | 202417043024-COMPLETE SPECIFICATION [03-06-2024(online)].pdf | 2024-06-03 |
| 7 | 202417043024-FORM 18 [04-06-2024(online)].pdf | 2024-06-04 |
| 8 | 202417043024-Proof of Right [08-08-2024(online)].pdf | 2024-08-08 |
| 9 | 202417043024-FORM-26 [08-08-2024(online)].pdf | 2024-08-08 |